> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Wave Life Sciences Reports Mixed Data on Obesity Therapy
- URL: https://www.fdaweb.com/wave-life-sciences-reports-mixed-data-on-obesity-therapy/
- Published: 2026-03-26T12:00:00.000Z
- Updated: 2026-09-14T13:36:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160887

Wave Life Sciences is reporting new interim Phase 1 data Thursday indicating that a 240 mg dose of its investigational obesity therapy WVE-007 produced stronger and more consistent reductions in key fat measures than a higher 400 mg dose, raising questions about dose-response dynamics in the early-stage trial. The results come from the ongoing INLIGHT study, which is evaluating the RNA interference-based therapy in overweight and obese individuals, according to the company.

At six months following a single dose, patients receiving 240 mg demonstrated statistically significant and clinically meaningful improvements in body composition. The data show that visceral fat decreased 14.3%, total fat declined 5.3%, and lean mass decreased 2.4%. The company emphasizes that these reductions were achieved in a relatively lower-BMI population (average \~32 kg/m²), suggesting potential for even greater effects in heavier patients in later-stage trials.

By contrast, the 400 mg cohort — reported at three months — showed more modest improvements. The data for the 400 mg dose showed that visceral fat decreased 5.0%, total fat declined 0.7%, and lean mass decreased 0.2% (essentially preserved), the company says.

On the surface, these results indicate that the higher dose delivered weaker fat reduction than the 240 mg dose, particularly for visceral fat, a key metabolic risk driver. However, Wave attributed the apparent discrepancy largely to differences in baseline patient characteristics, rather than diminished drug activity at higher doses. For example, it says patients in the 400 mg group had lower BMI overall, and they included a large subset (about 40%) with already healthy visceral fat levels. A post-hoc analysis showed that among patients with elevated visceral fat (greater than 500 g), the 400 mg dose achieved a -7.8% reduction at three months — closer to the response seen in the 240 mg group.

The company says WVE-007 is designed to reduce fat via lipolysis without muscle loss, a potential differentiator from incretin-based therapies, which are often associated with lean mass reduction. It plans to launch a Phase 2a study in higher-BMI patients (35–50 kg/m²) in the second quarter of 2026, where it expects clearer differentiation across doses and greater overall weight loss.